Dual HER2 blockade with pertuzumab+trastuzumab on the eve of a new era in the treatment of HER2-positive breast cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Dual HER2 blockade with pertuzumab + trastuzumab has been standard treatment for early and metastatic HER2 positive breast cancer (BC) for several years. The recent registration of a fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection opens up new perspectives for physicians and patients. The article discusses the role of dual targeted HER2 blockade in the complex treatment of patients with HER2 positive BC. The article provides an overview of data from key studies that have identified the place of the combination of pertuzumab+trastuzumab in modern algorithms for the treatment of HER2-positive BC. The data from studies of a fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection and the potential advantages of the new drug over intravenous pertuzumab and trastuzumab in the management of patients with HER2 positive BC are discussed.

Full Text

Restricted Access

About the authors

Lyudmila G. Zhukova

Loginov Moscow Clinical Scientific Center

Email: zhukova.lyudmila008@gmail.com
Dr. Sci. (Med.), Professor of RAS, Deputy Director for Oncology Moscow, Russia

E. V Artamonova

Pirogov Russian National Research Medical University; M.F. Vladimirsky Moscow Regional Research Clinical Institute; N.N. Blokhin National Medical Research Center of Oncology

Moscow, Russia

I. P Ganshina

N.N. Blokhin National Medical Research Center of Oncology

Moscow, Russia

I. V Kolyadina

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

K. A Vorontsova

Loginov Moscow Clinical Scientific Center

Moscow, Russia

O. V Sekhina

Loginov Moscow Clinical Scientific Center

Moscow, Russia

K. S Grechukhina

Loginov Moscow Clinical Scientific Center

Moscow, Russia

References

  1. Harbeck N., et al. Brest cancer. Nat Rev Dis Primers. 2019;5(1):66. doi: 10.1038/s41572-019-0111-2.
  2. Ozlem Y., Barutca S. «Biological subtypes of breast cancer: Prognostic and therapeutic implications. W J Clin Oncol. 2014;5(3):412. doi: 10.5306/wjco. v5.i3.412.
  3. Grinda T, et al. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 20082017 ESME cohort. ESMO Open. 2021;6:100114. doi: 10.1016/j.esmoop.2021.100114.
  4. Ibragimova Khava I.E., et al. Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry. Breast Cancer Res Treat. (2021):1-11. doi: 10.1007/s10549-021-06178-8.
  5. Loeser A.L., Peppercorn J.M., Burkard M.E., et al. Treatment-related side effects and views about dosage assessment to sustain quality of life: results of an advocate-led survey of patients with metastatic breast cancer (MBC). J Clin Oncol. 2021;39(Suppl. 15):abstr 1005. Doi: 10.1200/ JCO.2021.39.15_suppl.1005.
  6. Jennifer M., Gafni A., Moumjid N. Cancer care at home or in local health centres versus in hospital: Public policy goals and patients' preferences in the Rhone-Alps region in France. Health Policy. 2021;125(2):213-20. Doi: 10.1016/j. healthpol.2020.11.011.
  7. Wilson F.R., et al. Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis. Syst Rev. 2018;7(1):1-17. doi: 10.1186/s13643-018-0854-y.
  8. Balduzzi S., Mantarro S., Guarneri V, et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews. 2014;issue 6:CD006242. doi: 10.1002/14651858.CD006242.pub2.
  9. ishii K., Morii N., Yamashiro H. Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy. Core Evidence. 2019;14:51. doi: 10.2147/CE.S217848.
  10. Gianni L., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet. Oncol. 2012;13( 1):25-32. doi: 10.1016/S1470-2045(11)70336-9.
  11. Schneeweiss A., et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase ii cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278-84. doi: 10.1093/annonc/ mdt182.
  12. Piccart M., et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHiNiTY Trial: 6 Years' Follow-Up. J Clin Oncol. 2021;39(13):1448-57. doi: 10.1200/ JCO.20.01204.
  13. Swain S.M., et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724-34. doi: 10.1056/NEJMoa1413513.
  14. Swain S.M., et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet. Oncol. 2020;21(4):519-doi: 10.1016/S1470-2045(19)30863-0.
  15. Miles D.W., et al. Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator's chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Ann Oncol. 2020;31:S356-57. doi: 10.1016/j.annonc.2020.08.390.
  16. Клинические рекомендации «Рак молочной железы». 2021 г. URL: http://cr.rosminzdrav.ru/schema/379_4 (Доступ: август 2021).
  17. Giordano S.H., et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(26):2736-40. Doi: 10.1200/ JCO.2018.79.2697.
  18. Cardoso F., et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623-49. doi: 10.1016/j.annonc.2020.09.010.
  19. NCCN Breast Cancer Guidelines. Version 4, 2021 -April 28, 2021.
  20. Инструкция по медицинскому применению препарата Перьета® РУЛП-002034.
  21. Инструкция по медицинскому применению препарата Герцептин® П N015932/01. [instructions for medical use of the drug Herceptin® P N015932/ 01. (in Russ.)].
  22. De Cock E., Pivot X., Hauser N., et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Med. 2016;5:389-97. doi: 10.1002/cam4.573.
  23. Shivakumar S.P, Anderson D.R., Couban S. Catheter-associated thrombosis in patients with malignancy. J Clin Oncol. 2009;27:4858-64. doi: 10.1200/JCO.2009.22.6126.
  24. Jackisch C., Müller V., Maintz C., et al. Subcutaneous administration of monoclonal antibodies in oncology. Geburtshilfe Frauenheilkd. 2014;74:343-49. doi: 10.1055/s-0034-1368173.
  25. Fallowfield L., Osborne S., Langridge C., et al. implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study Breast. 2015;24:166-doi: 10.1016/j.breast.2015.01.002.
  26. Halozyme Therapeutics inc. HYLENEX recombinant (hyaluronidase human injection). Prescribing information. Available at: https:// www.accessdata.fda.gov/drugsatfdadocs/label/2016/021859s0231bl.pdf (Accessed September 2021).
  27. Frost G.i. Recombinant human hyaluronidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007;4:427-40. doi: 10.1517/17425247.4.4.427.
  28. Инструкция по медицинскому применению препарата Герцептин® ЛП-002743.
  29. Ismael G., Hegg R., Muehlbauer S., et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage i-iii Breast Cancer (HannaH study): a phase 3, open-label, multicentre randomised trial. Lancet. Oncol. 2012;13:869-
  30. doi: 10.1016/S1470-2045(12)70329-7.
  31. Pivot X., Gligorov J., Müller V., et al. Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: Cohort 2 of the PrefHer study. Cancer Res. 2013;73:Abstract P4-12-ll
  32. Wardley A., Canon J.L., Elsten L., et al. Flexible care in breast cancer. ESMO Open. 2021;6:100007. doi: 10.1016/j.esmoop.2020.100007.
  33. London Cancer Alliance. Care closer to home and medicines optimisation. Pilot Service Evaluation Report. London: London Cancer Alliance, 2015.
  34. Snell A., Ford M. Assessing the impact of a homecare/mobile chemotherapy unit co-ordinator using subcutaneous herceptin as an example [Poster. Taunton: Taunton and Somerset NHS Foundation Trust, 2016].
  35. Mordenti P, Proietto M., Citterio C., et al. [The treatment of cancer patients near their residence in the territorial structure "casa della salute": preliminary results in the province of piacenza (Italy)]. Recent Prog Med. 2018;109:337-41.
  36. Roe H. Impact of switching from intravenous to subcutaneous trastuzumab in the management of HER2 positive breast cancer. In: UKONS Annual Conference 2016, 11-12 November 2016, Brighton, UK.
  37. Abad R., Arenaza A., Bayo J., et al. Impacto en la eficiencia tras la optimizac on de recursos con la via subcuta' nea de trastuzumab y rituximab en los hospitales espa~noles: Proyecto H-Excelencia. In: 6th Tendiendo Puentes (Congreso De Oncologia Medica, Hematologia y Farmacia Oncohematologica), Toledo, Spain, 2018.
  38. Franken M.G., Kanters T.A., Coenen J.L., et al. A comparison of healthcare and societal costs of hospital-based and home-based subcutaneous injections of trastuzumab (PCN330). Value Health. 2019;22:S500. Abstract PCN330.
  39. Food and Drug Administration (FDA). Phesgo® (pertuzumab, trastuzumab, and hyaluronidase-zzxf). Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/761170s0001bl.pdf (Accessed September 2021).
  40. Phesgo® SmPC. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf (Accessed September 2021).
  41. Инструкция по медицинскому применению препарата Фесго®. ЛП-0073 1 7.
  42. Tan A.R., et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet. Oncol. 2021;22(1):85-97. doi: 10.1016/S1470-2045(20)30536-2.
  43. O'Shaughnessy J., et al. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. Eur J Cancer. 2021152:223-32. Doi: 10.1016/j. ejca.2021.03.047.
  44. ClinicalTrials.gov. An expanded access, single-arm, multicenter study to provide at home subcutaneous administration of pertuzumab and trastuzumab fixed-dose combination (PH FDC SC) for patients with HER2-positive breast cancer during the COVID-19 pandemic, https://clinicaltrials.gov/ct2/show/NCT04395508 (Accessed August 2021).
  45. DuMond B., et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach. J Oncol Pharm Pract. 2021:1078155221999712. doi: 10.1177/1078155221999712.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies